Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

Background and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: This post hoc analysis evaluated clinical, endoscopic,...

Full description

Bibliographic Details
Main Authors: Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, Marc Ferrante, Satoshi Motoya, Remo Panaccione, Joana Torres, Ryan C. Ungaro, Kristina Kligys, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Geert D'Haens
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Gastro Hep Advances
Subjects:
Biologics
Crohn’s Disease
Disease Duration
Interleukin 23
Risankizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572324000293

Internet

http://www.sciencedirect.com/science/article/pii/S2772572324000293

Similar Items